Close Menu

NEW YORK (GenomeWeb) — Personal Genome Diagnostics announced today that its non-invasive pan-cancer plasma assay will be used in a clinical trial evaluating Bristol-Myers Squibb's cancer drugs Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with specific genetic mutations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.